#EULAR2018 – Lenabasum Safe and Effective in Diffuse Scleroderma Patients, One-year Trial Data Show
Lenabasum, an investigational treatment of diffuse cutaneous systemic sclerosis by Corbus Pharmaceuticals, was shown to be safe, well-tolerated and of benefit to patients treated for one year in a long-term extension of a Phase 2 trial. Latest results of the JBT101-SSc-001 study (NCT02465437) will be discussed at the European…